Body mass index as a possible predictor of the development of endocrine immune-mediated adverse events during immune checkpoint inhibitors therapy

A. A. Glibka; N. V. Mazurina; E. A. Troshina; K. A. Sarantseva; G. Yu. Kharkevich; M. V. Volkonskii; A. R. Elfimova

doi:10.14341/omet13044-10134

For citations:

Glibka A.A., Mazurina N.V., Troshina E.A., Sarantseva K.A., Kharkevich G.Yu., Volkonskii M.V., Elfimova A.R. Body mass index as a possible predictor of the development of endocrine immune-mediated adverse events during immune checkpoint inhibitors therapy. Obesity and metabolism. 2024;21(1):42-57. (In Russ.) https://doi.org/10.14341/omet13044

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).

ISSN 2071-8713 (Print)
ISSN 2306-5524 (Online)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Obesity and metabolism

For citations:

Cookies policy